Strategic funding Capitalize on Switch Therapeutics’ recent $52M Series A and preclinical CASi platform to pursue partnerships or co-development opportunities with biopharma companies seeking novel RNAi-based therapeutics for CNS and systemic indications.

Technical leadership Leverage the appointment of a new Chief Technology Officer and seasoned executives to position as a partner for outsourced R&D collaborations, contract research, or advisory roles that align with advancing the CASi platform and pipeline.

Pipeline potential Identify potential licensing or collaboration deals around the CASi technology, targeting unmet neurological and systemic diseases where selective RNAi delivery could offer competitive differentiation.

Clinical readiness Target biopharma players with late-preclinical to preclinical portfolios interested in acquiring or co-developing novel gene knockdown modalities to accelerate time-to-market and diversify modality mix.

Strategic partnerships Propose joint venture or strategic investment discussions with Switch Therapeutics’ senior team to scale platform validation, leverage external funding, and build a robust pipeline through external funding channels.